Federal Register / Vol. 80, No. 6 / Friday, January 9, 2015 / Notices 1417 

Director (CAJS1), Office of the Safety, 

Security and Asset Management (CAJS), 

and renumber the remaining items 

accordingly. 

Delete item (7) of the functional 

statement for the Physical Security 

Laboratory and Technical Branch 

(CAJSEB), Security Services Office 

(CAJSE), Office of the Safety, Security 

and Asset Management (CAJS), and 

renumber remaining items accordingly. 

Delete item (11) of the functional 

statement for the Physical Security 

Operations Branch (CAJSEC), Security 

Services Office (CAJSE), Office of the 

Safety, Security and Asset Management 

(CAJS), and renumber remaining items 

accordingly. 

After the mission statement for the 

Security Services Office (CAJSE), insert 

the following: 

Internal Emergency Management 

Branch (CAJSEE). To lead a 

comprehensive internal emergency 

management program that efficiently 

coordinates CDC resources to, first and 

foremost, protect lives, then to safeguard 

the environment and property through 

mitigation, preparedness training, 

response, continuity and recovery from 

all natural, man-made and technological 

hazards that may impact CDC facilities: 

(1) Implements, maintains, and updates 

CDC’s Occupant Emergency Plan/

Program (OEP); (2) conducts and 

evaluates annual tabletop, functional, 

and full-scale exercises for all CDC 

facilities with Designated Officials and 

Occupant Emergency Organizations 

(OEO); (3) recommends future 

emergency management and emergency 

response-related programs, policies, 

and/or procedures; (4) provides 

leadership and coordination in planning 

and implementation for internal 

emergencies; and (5) provides 

leadership and coordination in planning 

and implementation for internal 

emergency incidents affecting the CDC 

facilities, including incident response 

and support. 

James D. Seligman, 

Acting Chief Operating Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2015–00146 Filed 1–8–15; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 79 FR 32739–32740, 

dated June 7, 2014) is amended to 

reflect the reorganization of the Global 

Immunization Division within the 

Center for Global Health. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

Delete in its entirety the title and the 

mission and function statements for the 

Global Immunization Division (CWK) 

and insert the following: 

Global Immunization Division (CWK). 

The Global Immunization Division 

(GID) protects the health of Americans 

and global citizens by preventing 

disease, disability, and death worldwide 

from vaccine-preventable diseases. In 

carrying out its mission, GID: (1) 

Provides national leadership and 

coordination of the Center for Global 

Health (CGH) efforts to eradicate polio; 

eliminate measles and rubella in World 

Health Organization (WHO) regions; 

strengthens global surveillance to 

prevent, detect, and respond to vaccine 

preventable diseases; strengthens 

routine immunization programs; 

introduces new and under-utilized 

vaccines; and promotes safe injection 

practices in collaboration with 

international organizations and CDC 

Centers/Institute/Offices (CIOs); (2) 

provides technical expertise to global 

partners—WHO, United Nations 

International Children’s Emergency 

Fund (UNICEF), Global Alliance for 

Vaccine Immunization (GAVI), and the 

Bill and Melinda Gates Foundation 

(BMGF)—involved in global 

immunization activities and participates 

in international advisory group 

meetings on immunization issues; (3) 

ensures provision of technical expertise 

on evidence-based research, strategies, 

and policy at global and country levels 

in collaboration with multilateral and 

bilateral partners; (4) collaborates with 

other countries and administers grants 

to WHO, Pan American Health 

Organization (PAHO), UNICEF, and 

other international partners and 

advocacy groups as appropriate for the 

provision of technical, programmatic, 

and laboratory support, and vaccine 

procurement for initiatives to support 

global immunization targets; (5) 

improves surveillance for polio, 

measles, rubella, and other vaccine 

preventable diseases by working with 

individual countries and the WHO 

regional offices to improve surveillance 

and to collaborate with groups within 

and outside CDC to expand 

environmental surveillance; (6) achieves 

global immunization targets by 

supporting the strengthening of the 

implementation of national 

immunization policies; (7) strengthens 

appropriate vaccination policy 

development and implementation, 

identifies barriers to vaccine acceptance, 

and develops communication strategies 

to promote vaccine uptake and disease 

reduction; (8) develops strategies to 

improve the technical skills and 

problem-solving abilities of program 

managers and health care workers in 

other countries; (9) prepares 

immunization articles based on findings 

for publication in international 

professional journals and for 

presentation at international 

conferences; and (10) provides technical 

and operational leadership for CDC’s 

activities in support of the initiatives. 

Office of the Director (CWK1). (1) 

Provides leadership, management, and 

oversight for all division activities 

including administrative, budget, 

finance, research, workforce 

development, management and 

operations; (2) assists leadership in the 

formulation and defense of GID budget 

requests, and monitors and seeks 

strategies to mitigate division risks; (3) 

provides coordination and oversight of 

the division’s personnel actions 

including liaison with CGH and CDC’s 

human resource office; (4) provides 

oversight for workforce planning, 

recruitment, deployment, field staff 

support, professional development, and 

monitoring and evaluation; (5) develops 

and promotes partnerships with other 

organizations to support global 

immunization activities and works 

closely with partners in academia; (6) 

liaises and coordinates with other CDC 

offices engaged in global immunization 

activities; (7) provides leadership and 

oversight for scientific and 

programmatic activities related to the 

implementation of GID’s objectives and 

ensures that the research and economic 

portfolios are integrated across the 

branches and with field activities; (8) 

identifies program policy priorities 

through strategic planning and other 

processes as appropriate; (9) clears all 

scientific publications from the division 

working in close collaboration with 

management of GID; (10) provides 

coordination of the division’s 

communications activities including 

liaison with other CDC communications 

offices and those of our partner 

agencies; (11) represents CDC, CGH, and 

the division at global and national 

meetings and other fora for global 

immunization activities; (12) provides 


rljohnson on DSK3VPTVN1PROD with NOTICES
1418 Federal Register / Vol. 80, No. 6 / Friday, January 9, 2015 / Notices 

oversight for all Embassy/International 

Cooperative Administrative Supportive 

Services costs for the division’s field 

staff; and (13) works in close 

collaboration and interfaces with CGH 

and other CIOs, global immunization 

partners, and other collaborating 

partners in matters relating to program 

development and research. 

Polio Eradication Branch (CWKB). (1) 

Achieves global polio eradication in 

partnership with the Global Polio 

Eradication Initiative (GPEI) and 

optimize polio investments toward 

future health goals; (2) acts as CDC’s 

lead for polio eradication activities in 

countries within Africa in partnership 

with GPEI; (3) works with polio free 

regions to strengthen their efforts to 

remain polio-free, particularly in the 

areas of surveillance, outbreak 

preparedness, containment and legacy 

planning; (4) improves surveillance for 

polio by working with individual 

countries, WHO regional offices, and 

groups within and outside CDC to 

expand environmental surveillance; (5) 

is prepared to respond quickly to 

outbreaks of wild poliovirus and 

circulating vaccine-derived 

polioviruses; (6) leads work in countries 

at high risk for polio; (7) leads activities 

to achieve poliovirus containment by 

the required deadlines; (8) oversees 

technical aspects of specific polio 

activities funded by CDC; (9) prepares 

countries for certification; (10) leads or 

collaborates in research to support polio 

eradication goals; (11) identifies 

opportunities to leverage polio 

eradication assets to promote 

sustainable improvements in routine 

immunization systems, in collaboration 

with the Immunization Systems Branch; 

(12) defines and ensures a sustainability 

legacy for the polio eradication program 

in addition to polio eradication itself 

and identifies opportunities to 

implement strategies toward this goal; 

(13) coordinates with key partners 

within and outside CDC; (14) promotes 

the National Stop Transmission of Polio 

(NSTOP)program; (15) develops 

priorities for CDC’s involvement in 

polio eradication research and 

innovation activities; (16) collects and 

analyzes data on wild polio virus and 

vaccine perceived polio virus incidence, 

surveillance performance and 

immunization status based on acute 

flaccid paralysis surveillance and 

supplemental immunization activities 

implementation quality; (17) provides 

support to regional and country teams 

in assessing risk of outbreaks of wild 

poliovirus and circulating vaccinederived polioviruses; responding to 

outbreaks; planning and implementing 

mitigating activities to prevent 

outbreaks; improving surveillance; and 

assisting in development of 

documentation to support certification 

and containment; and (18) supports the 

completion of global polio eradication 

through strengthening surveillance, 

innovation and research. 

Accelerated Disease Control and 

Vaccine Preventable Diseases 

Surveillance Branch (CWKC). (1) 

Achieves accelerated disease control 

goals for vaccine preventable diseases 

(VPD), with a high focus on eliminating 

measles and rubella in WHO regions in 

partnership with the Measles and 

Rubella Initiative (MRI), and 

strengthening global surveillance to 

prevent, detect and respond to VPDs; (2) 

leads global and regional measles 

elimination goals; (3) provides expert 

technical input toward development, 

evaluation, and improvement of 

program activities and strategies to 

mitigate risk and achieve global and 

regional measles elimination goals; (4) 

monitors measles incidence and risk 

through development and analysis of 

high quality surveillance data and risk 

estimates, estimating burden of disease/ 

death and verifying elimination; (5) 

develops and maintains outbreak 

preparedness and respond rapidly to 

outbreaks; (6) oversees the technical 

aspects of measles activities funded by 

CDC; (7) leads global and regional 

rubella control and elimination goals; 

(8) provides expert technical input to 

countries on the development and 

implementation of national plans of 

action for rubella vaccine introduction 

and the control and elimination of 

rubella and congenital rubella 

syndrome; (9) leads activities of the 

MRI, including participation on working 

groups, as appropriate; (10) strengthens 

labs and lab networks to ensure 

appropriate and timely specimen 

collection, testing, and result 

dissemination; (11) develops and 

maintains outbreak control strategies, 

including developing mathematical 

models to estimate the target age range 

for achieving program goals; (12) 

provides technical support to reach 

global or regional goals for control of 

targeted VPDs; (13) provides expert 

technical input towards development, 

evaluation, and improvement of 

program activities and strategies to 

mitigate risk and achieve global and 

regional VDP control goals; (14) 

monitors prevalence, incidence and risk 

through development and analysis of 

high quality surveillance data and risk 

estimates, estimating burden of disease/ 

death and verifying elimination; (15) 

conducts research and evaluation to 

maximize the cost-effectiveness of 

elimination and outbreak control 

strategies; (16) oversees the technical 

aspects of targeted VPD activities 

funded by CDC; (17) provides ongoing 

support for development, 

implementation, quality, and use of 

VPD surveillance; (18) evaluates VPD 

surveillance systems and improves the 

quality, analysis, and use of surveillance 

data for program action and decisionmaking; (19) provides technical 

assistance in establishing and 

maintaining surveillance for diseases 

prevented by new or underutilized 

vaccines; (20) conducts research and 

evaluation to maximize surveillance 

performance and cost-effectiveness; and 

(21) leads innovative research and 

development to strengthen surveillance 

and improve laboratory diagnosis. 

Immunization Systems Branch 

(CWKD). (1) Achieves global 

immunization targets by supporting the 

strengthening of the implementation of 

national immunization policies; 

identifies strategies to increase vaccine 

demand; promotes the appropriate 

introduction and use of quality 

vaccines; and strengthens routine 

immunization program delivery and 

equitable access to vaccines, while 

promoting synergies through the child 

health agenda; (2) leads development 

and implementation of effective 

communication strategies that address 

issues related to vaccine demand and 

uptake; (3) identifies caregiver, 

provider, and community determinants 

that affect vaccine demand, in order to 

develop evidence-based strategies to 

remove barriers and increase demand 

for immunization; (4) evaluates vaccine 

policy development, implementation, 

and impact, and advocates for policies 

demonstrated to support acceptance of 

vaccine; (5) accelerates progress toward 

achieving the millennium development 

goals of mortality reduction and disease 

prevention by advocating and 

promoting the appropriate and equitable 

introduction of new and underutilized 

vaccines; (6) builds evidence and 

rationale for vaccine introduction; (7) 

secures WHO-prequalification; (8) 

provides technical and programmatic 

assistance to countries to introduce new 

and underutilized vaccines into their 

national immunization programs; (9) 

evaluates effectiveness of introduction 

of new and underutilized vaccines in 

terms of uptake, impact on existing 

immunization program function, and 

potential impact on disease burden; (10) 

works with VPD Surveillance Team and 

CDC subject matter experts to build 

country capacity for future introduction 

of new and underutilized vaccines; (11) 


rljohnson on DSK3VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 6 / Friday, January 9, 2015 / Notices 1419 

leads inactive polio virus introduction 

to immunization systems in oral polio 

virus using countries as mandated 

through the Immunization Management 

Group of the Global Polio Eradication 

Initiative; improves routine 

immunization systems globally (or 

improves access to and utilization of 

vaccines globally through strengthening 

of routine immunization systems); (12) 

develops, evaluates, and scales-up 

evidence-based strategies to tackle 

inequities in access to and delivery of 

vaccines; (13) develops evaluates, and 

scales-up comprehensive and 

coordinated approaches to integrate 

immunization services; (14) promotes 

innovation to improve routine 

immunization program efficiencies and 

increase coverage and impact; (15) 

conducts advocacy to national programs 

on the need to strengthen immunization 

system abilities to monitor, assess and 

respond to issues related to vaccine 

safety; and (16) conducts operational 

research to identify and test 

interventions to improve the access and 

utilization of immunization services and 

provide guidance on what areas are in 

need of workforce capacity building 

activities. 

Strategic Information and Workforce 

Development Branch (CWKE). (1) Builds 

workforce, systems, and information 

capacity to effectively deliver 

immunization services in selected 

countries; (2) provides technical 

assistance and support, guidance, and 

advice on statistical analysis and study 

design, data management, and data 

integrity to the GID; (3) provides 

statistical expertise to support internal 

data management needs of the division 

and field staff (standard setting for 

record keeping, archiving, ensuring 

reproducibility of analyses); (4) 

collaborates with branch and team level 

leadership and GID management to 

ensure that statistical and 

methodological standards continue to 

remain an integral part of planning, 

conduct, and review of science and 

program within GID including with the 

context of the official clearance process; 

(5) provides GID statistical 

representation on internal and external 

committees and work groups and at 

relevant meetings, workshops, and fora; 

(6) promotes capacity building for polio, 

other VPDs and immunization functions 

in partnership with WHO and UNICEF 

through recruiting, coordinating training 

of, and deploying STOP teams; (7) 

promotes capacity building for polio, 

other VPDs and immunization functions 

in partnership with WHO and UNICEF; 

(8) leads the development of strong 

national immunization programs and 

systems through workforce capacity 

development; (9) ensures recruitment 

for training and WHO deployment for 

each STOP team; (10) creates and 

maintains strategic partnerships and 

collaborations and provides technical 

assistance to develop and evaluate 

sustainable programs aimed at 

increasing capacity and effectiveness of 

workforce responsible for implementing 

immunization programs; (11) conducts 

operational research to identify, 

implement and evaluate interventions 

aimed at improving immunization (or 

integrated public health) workforce 

effectiveness and contributes to the 

scientific knowledge base regarding 

interventions aimed at improving 

immunization workforce effectiveness; 

(12) leads strengthening routine 

immunization systems as mandated 

through the Immunization Management 

Group of the Global Polio Eradication 

Initiative; and (13) leads the 

development of strong immunization 

systems through improving quality, 

management, and use of immunization 

data and providing specific technical 

skills for program evaluation to include 

strategic information, informatics and 

information systems, program 

evaluation, polio eradication and 

endgame strategy, and operational 

research. 

James D. Seligman, 

Acting Chief Operating Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2015–00145 Filed 1–8–15; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifiers: CMS–10249 and 

CMS–10545] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, HHS. 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

any of the following subjects: (1) The 

necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments must be received by 

March 10, 2015. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number (OCN). To be 

assured consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: 

CMS, Office of Strategic Operations 

and Regulatory Affairs, Division of 

Regulations Development, Attention: 

Document Identifier/OMB Control 

Number ____, Room C4–26–05, 7500 

Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ Web site address at 

http://www.cms.hhs.gov/

PaperworkReductionActof1995. 

2. Email your request, including your 

address, phone number, OMB number, 

and CMS document identifier, to 

Paperwork@cms.hhs.gov. 

3. Call the Reports Clearance Office at 

(410) 786–1326. 

FOR FURTHER INFORMATION CONTACT: 

Reports Clearance Office at (410) 786– 

1326. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 


rljohnson on DSK3VPTVN1PROD with NOTICES